An octogenarian Japanese-American woman with advanced Alzheimer’s disease, who had spoken mostly in single syllables and required full-time care for years, exhibited improvements in multiple functions after receiving a high dose of psilocybin-containing mushrooms, according to a recent case report.
The patient, with a 10-year history of Alzheimer’s including five years of marked hypofunction, received 5 grams of Enigma strain mushrooms.
Approximately 19 hours later, she began to speak spontaneously in an autobiographical manner. Over subsequent days and weeks, she regained urinary continence, improved ambulation, dressed herself independently, showed increased emotional responsiveness, and engaged socially, per a case report published in late May, 2026.
A follow-up 3-gram dose one month later was associated with greater verbal expressivity, humor, and agility.
The report, titled “Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case report,” appeared in Frontiers in Neuroscience. Authors Marcos Lago, Mariana Cerveira, and Joe Xavier Simonet from Brazil’s Associação Cruz de Ankh described the changes as temporary and not indicative of disease reversal.
Details from the Case
The woman lived with continuous family supervision. Baseline symptoms included chronic urinary incontinence, executive dysfunction, dysphagia, dependent mobility, flat affect, and severe reduction in spontaneous communication. No formal biomarker confirmation or advanced neuroimaging was available.
The acute phase after the 5-gram dose involved autonomic activation, suspected hyperthermia, profuse sweating, and a prolonged, deep-sleep-like state. Spontaneous speech emerged later.
Improvements included restoration of continence—even at night—independent dressing, better walking, sustained eye contact, reciprocal smiling, and contextual memory retrieval, such as asking about a family member and recognizing a vehicle.
During the second session, she described positive visions, including surfing with her son, and spontaneously stated, “It is pleasant to come here.” Gains persisted for weeks but were transient.
The authors noted limitations: single-case design, no controls, no scans, and inability to prove causality. They wrote that the findings “do not imply disease reversal but suggest that residual functional capacity may persist in late-stage neurodegeneration and may become transiently accessible under specific neuromodulatory conditions.”
Psilocybin acts on serotonin 5-HT2A receptors, altering brain networks and promoting plasticity in preclinical models. This case builds on broader interest in psilocybin. A 2024 review in the same journal discussed its potential for Alzheimer’s via neuroplasticity, anti-inflammation, and network connectivity.
Alzheimer’s in the U.S.
An estimated 7.4 million Americans age 65 and older are living with Alzheimer’s in 2026, according to the Alzheimer’s Association. This represents about 1 in 9 people in that age group. Projections indicate the number could reach 13.8 million by 2060 without medical breakthroughs.
Deaths attributed to Alzheimer’s have risen sharply. Official counts show an increase of more than 140% between 2000 and 2022 in some reports, while deaths from stroke, heart disease, and HIV decreased. Updated 2026 report data show deaths more than doubled (approximately 134%) from 2000 to 2024, with 116,022 Alzheimer’s deaths recorded in 2024.
Alzheimer’s ranks as a leading cause of death for those 65 and older.
Caregiving demands are heavy. Nearly 13 million Americans provide unpaid care, contributing an estimated 19 billion hours valued at hundreds of billions of dollars annually. Total health and long-term care costs for dementia are projected to be near $400 billion in 2026.
While prevalence grows with an aging population, some studies indicate that age-adjusted dementia incidence has declined in Europe and North America—by about 13% per decade in recent decades—linked to improved cardiovascular health and education, as reported in Neurology. However, total cases continue rising due to demographics.
Potential Impact and Next Steps
The case report suggests psilocybin might temporarily “unlock” lingering abilities by modulating brain networks, but experts emphasize the need for controlled trials. No large-scale evidence yet supports psilocybin as a treatment for advanced Alzheimer’s.
Clinical research on psilocybin for Alzheimer’s-related symptoms, such as depression in mild cognitive impairment or early Alzheimer’s, is underway. Johns Hopkins University has conducted a pilot study (NCT04123314). Other trials explore its effects in related conditions, though advanced dementia data remains limited.
Psilocybin is a Schedule I substance under federal law, limiting access. Some states have moved toward regulated access or research. The FDA has granted breakthrough designations for psilocybin in depression and advanced trials for other indications, but broad Alzheimer’s approval is not imminent.
Researchers call for rigorous studies with imaging, biomarkers, and controls to assess safety and efficacy in dementia populations.
